Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer

Scientists conducted a Phase I/II single institution study combining chemotherapy gemcitabine and nab-paclitaxel, CCR2/5 inhibitor BMS-813160, and nivolumab for four 28-day cycles for patients with borderline resectable or locally advanced PDAC.